Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
- 26 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 342-349
- https://doi.org/10.1016/j.clcc.2021.09.009
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practiceColorectal Cancer, 2018
- Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsInternational Journal of Clinical Oncology, 2017
- Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyThe Oncologist, 2017
- FDA Approval Summary: TAS-102Clinical Cancer Research, 2017
- Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programmeESMO Open, 2017
- Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single InstitutionClinical Colorectal Cancer, 2016
- Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyBMC Cancer, 2016
- TAS-102, a novel antitumor agent: A review of the mechanism of actionCancer Treatment Reviews, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014